SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

A Wells Fargo downgrade to Underweight, citing worrying engagement trends and a potentially weaker original-content slate alongside rising live-sports costs, has driven the discussion and selling pressure. Traders are divided between viewing the call as a dubious, opportunistic downgrade and buying the dip, while others worry about intensifying competition and slowing content-driven growth.

The Boeing Co. is an aerospace company, which engages in the manufacture of commercial jetliners and defense, space, and security systems. It operates through the following segments: Commercial Airplanes (BCA), Defense, Space and Security (BDS), and Global Services (BGS). The Commercial Airplanes segment includes the development, production, and market of commercial jet aircraft and provides fleet support services, principally to the commercial airline industry worldwide. The Defense, Space and Security segment refers to the research, development, production and modification of manned and unmanned military aircraft and weapons systems for global strike, including fighter and combat rotorcraft aircraft and missile systems, global mobility, including tanker, rotorcraft and tilt-rotor aircraft, and airborne surveillance and reconnaissance, including command and control, battle management and airborne anti-submarine aircraft. The Global Services segment provides services to commercial and defense customers. The company was founded by William Edward Boeing on July 15, 1916, and is headquartered in Arlington, VA.

Boeing Co.

Boeing Co

Boeing is drawing attention after CEO Kelly Ortberg said stabilizing 737 MAX production is taking longer than expected because of wing-production constraints, while 787 ramp-up and potential China-order expectations also faced uncertainty. Traders largely viewed the comments as a negative operational update and criticized the resulting selloff as an overreaction, with the potential SPEEA strike adding further risk.

Boost Run, Inc. is a provider of scalable cloud infrastructure purpose-built for enterprise AI and high-performance computing workloads. The platform delivers GPU compute, CPU nodes, managed Kubernetes orchestration, and shared storage through an intuitive management console and a robust API layer, enabling organizations to provision and scale resources across thousands of nodes in minutes. The company was founded on September 5, 2025 and is headquartered in Northbrook, IL.

Boost Run Inc. - Ordinary Shares - Class A

Boost Run Inc.

Preliminary inclusion in the Russell 2000 and Russell 3000 is driving attention, with traders anticipating passive-fund buying and increased volume because of the stocks relatively small float. The community is broadly bullish on the index catalyst and recent analyst upgrades, though some remain concerned about insider selling, dilution, and execution risk in the AI infrastructure business.

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

Attention centers on the upcoming Starship Flight 14 launch, with traders debating whether a successful test can extend the stocks momentum; NASAs selection of SpaceX for the StarBurst mission adds to the bullish narrative. Bears counter that the valuation is excessive and upcoming lockup expirations and launch risk could create selling pressure, while others focus on index-rebalance buying and heavy options positioning.

Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in Cleveland, OH.

Abeona Therapeutics Inc

FDA approval of Ultragenyxs FAYUVI gene therapy, formerly Abeonas UX111, is driving attention as traders expect Abeona to receive commercial milestone payments and royalties. The community is largely bullish on the new revenue stream and potential short squeeze, though some traders caution that the rare pediatric indications small market may limit the financial impact.

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010 and is headquartered in Novato, CA.

Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc

FDA approval of Fayuvi, the first treatment for Sanfilippo syndrome type A, is driving attention, alongside the associated Priority Review Voucher and potential commercial launch. Traders are broadly bullish on the approval and possible short squeeze, but debate whether the muted share-price reaction reflects limited patient numbers, commercialization and cash-burn concerns, or profit-taking.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class C

Unconfirmed reports that Googles next Gemini model may be showing recursive self-improvement capabilities are driving much of the bullish attention, with traders speculating this could strengthen Alphabets position in the AI race. Skeptics question the leaks authenticity and continue to debate high AI spending, valuation, regulatory risk, and macroeconomic pressure.

NEAR Protocol is the blockchain for AI. A high-performance, AI-native platform built to power the next generation of decentralized applications and intelligent agents. It provides the infrastructure AI needs to transact, operate, and interact across Web2 and Web3. NEAR combines three core elements: User-Owned AI, which ensures agents act in users’ best interests; Intents and Chain Abstraction, which eliminate blockchain complexity for seamless, goal-driven transactions across chains; and a sharded blockchain architecture that delivers the scalability, speed, and low-cost execution needed for real-world AI and Web3 use. This integrated stack makes NEAR the foundation for building secure, user-owned, AI-native applications at internet scale.

Near

A sharp NEAR rally is drawing attention, with traders citing its AI-agent and chain-abstraction narrative alongside NEAR Intents/Confidential Intents usage and claimed fee-based buybacks. Others argue the move is mainly a liquidity event or short squeeze, pointing to the lack of a clearly confirmed new catalyst.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

Escalating Middle East conflict, including attacks on Saudi oil infrastructure and disruption risks around the Strait of Hormuz, is driving attention to USO as traders debate a potential supply shock and diesel squeeze. Bulls expect prolonged outages to support crude, while bears point to possible ceasefire or pipeline restarts, demand destruction, and inventory builds as reasons for a sharp reversal.

Securitize Corp. is a financial technology company, which engages in the provision of regulated infrastructure for the issuance, management, trading, and administration of tokenized real-world assets (RWAs). The company was founded on October 17, 2025 and is headquartered in Miami, FL.

Securitize Corp.

An SEC five-year innovation exemption allowing certain platforms to facilitate trading in tokenized U.S. stocks is driving attention, with traders viewing it as a regulatory tailwind for Securitizes digital-asset infrastructure. The community is largely bullish on the tokenization theme and breakout momentum, while some remain concerned about profitability, valuation, and short-term volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Wall Street Analysts See a 258.21% Upside in Adicet Bio (ACET): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 258.2% in Adicet Bio (ACET). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Is Adicet Bio (ACET) Outperforming Other Medical Stocks This Year?

Here is how Adicet Bio, Inc. (ACET) and Centene (CNC) have performed compared to their sector so far this year.

Adicet Bio to Participate in Fireside Chat at H.C. Wainwright 28th Annual Global Investment Conference

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR-T cell and in vivo CAR-T therapies for autoimmune diseases, hematologic malignancies and solid tumors, today announced that Chen Schor, President and Chief Executive...

Adicet Bio Announces Completion of Last Patient Visit for Planned Analysis of prula-cel (formerly ADI-001) Study in Patients with Systemic Lupus Erythematosus With or Without Lupus Nephritis and Provides Corporate Update

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR-T cell and in vivo CAR-T therapies for autoimmune diseases, hematologic malignancies and solid tumors, today announced completion of the last patient visit for the planned...

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR T cell and in vivo CAR T therapies for autoimmune diseases, hematologic malignancies and solid tumors, today announced it granted an inducement award on August 31, 2026. One...

Adicet Bio Announces FDA Clearance of IND Application for ADI-212

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR T cell and in vivo CAR T therapies for autoimmune diseases, hematologic malignancies and solid tumors, today announced that the U.S. Food and Drug Administration (FDA) has...

Here's Why You Should Add ACET Stock to Your Portfolio Now

Adicet Bio advances prula-cel in autoimmune diseases while pursuing new opportunities in prostate cancer and in vivo CAR-T.

Are Medical Stocks Lagging  Adicet Bio (ACET) This Year?

Here is how Adicet Bio, Inc. (ACET) and Agilent Technologies (A) have performed compared to their sector so far this year.

Wall Street Analysts Think Adicet Bio (ACET) Could Surge 301.57%: Read This Before Placing a Bet

The consensus price target hints at a 301.6% upside potential for Adicet Bio (ACET). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

All You Need to Know About Adicet Bio (ACET) Rating Upgrade to Buy

Adicet Bio (ACET) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Adicet Bio, Inc. is a clinical stage biotechnology company, which engages in discovering and developing allogeneic gamma delta T cell therapies for cancer. It also focuses on developing a pipeline of “off-the-shelf” gamma delta T cells. The company was founded by Aya Jakobovits in November 2014 and is headquartered in Boston, MA.

Adicet Bio Inc

Bullish Sentiment

No more this year

One more

Two more

The Federal Reserve raised interest rates by a quarter point to a range of 3.75%-4.00% on Wednesday, its first hike since July 2023, but Fed Chair Kevin Warsh signaled the tightening cycle isn't over. How many more rate hikes do you expect by the end of 2026? Vote and explain your reasoning in the comments.

The Fed hiked rates 25bps yesterday, its first since 2023, but signaled it&#39;s not done - projections point to one or two more hikes this year. How many total hikes do you expect by year-end?

Stocktwits

The Fed hiked rates 25bps yesterday, its first since 2023, but signaled it's not done - projections point to one or two more hikes this year. How many total hikes do you expect by year-end?

Current Price	$9.01
Prev Close	$9.05
Open	$9.20
Dividend Yield	0.00%
50-Day Moving Average	$8.80
Beta	1.36
Avg. Volume	95,216.79
PE Ratio	-0.78

52-Week High	$17.44
52-Week Low	$6.01
Market Capitalization	$84.72M
EPS (Annual)	-$16.95
Price to Book	0.70
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

ACET Fundamentals